Mutagenicity of combined immunosuppressants.
Yu
Y
Y
Department of Surgery, University of Tsukuba, Ibaraki, Japan.
Yuzawa
K
K
Otsuka
M
M
Fukao
K
K
D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004347:Drug Interactions; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D066298:In Vitro Techniques; D008214:Lymphocytes / Q000187:drug effects; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D009153:Mutagens / Q000008:administration & dosage / Q000009:adverse effects*; D012263:Ribonucleosides / Q000008:administration & dosage / Q000009:adverse effects; D012854:Sister Chromatid Exchange / Q000187:drug effects*
D007166:Immunosuppressive Agents; D009153:Mutagens; D012263:Ribonucleosides; C010052:mizoribine; D016572:Cyclosporine; D015122:Mercaptopurine